| Luteinizing hormone releasing hormone agonist for postpartum contraception. | |
| | |
MedLine Citation:
|
PMID: 8739514 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To compare the effects of a GnRH agonist upon ovarian function, bleeding pattern, and nursing practice in two groups of Mexican women during the postpartum period. DESIGN AND PATIENTS: Two doses of a GnRH agonist (300-600 micrograms) were investigated during the postpartum period in fully breastfeeding mothers at 6 weeks postpartum. A total of 29 women who desired to breast feed for at least 6 months were allocated in three study groups; group I (control); group II, taking 300 micrograms; and group III, taking 600 micrograms. RESULTS: After treatment initiation, an increase of estrone levels was observed among treated women; thereafter, irregular fluctuations of estrone levels were observed, mainly among women from group III. All the control women and two participants from group III ovulated during the study. Moderate bleeding was registered in most of the women from group I, while amenorrhea and spotting were observed in participants from groups II and III, respectively. There was no significant effect of the treatment on nursing practice between groups. CONCLUSION: GnRH agonists have advantages over steroids for hormonal contraception during the postpartum period in breastfeeding women. Symptoms of hypoestrogenism were not reported any time in either the controls or the treated groups, as estrone levels were not suppressed to menopausal values. Once-daily administration of GnRH agonist could be a reliable, acceptable and safe contraceptive method during the postpartum period in breastfeeding women. More information is required to establish GnRH analog contraceptive efficacy. |
| | |
Authors:
|
S B Mayagoitia; C Hernández-Morales; A M Macías; R R Vega |
Related Documents
:
|
16879904 - The physical challenges of early breastfeeding. 11138864 - Beyond marital status: relationship type and duration and the risk of low birth weight. 2750724 - Breast cancer and breastfeeding: results from an australian case-control study. 12160594 - Trends in reproductive, smoking, and other chronic disease risk factors by birth cohort... 9599344 - Case in point. counseling about hormone replacement therapy. 22570144 - Combined effect of prenatal solvent exposure and gstt1 or gstm1 polymorphisms in the ri... |
Publication Detail:
|
Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Advances in contraception : the official journal of the Society for the Advancement of Contraception Volume: 12 ISSN: 0267-4874 ISO Abbreviation: Adv Contracept Publication Date: 1996 Mar |
Date Detail:
|
Created Date: 1996-10-10 Completed Date: 1996-10-10 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8607435 Medline TA: Adv Contracept Country: NETHERLANDS |
Other Details:
|
Languages: eng Pagination: 27-41 Citation Subset: IM |
Affiliation:
|
Department of Reproductive Biology, School of Medicine, University of Coahuila, C.P., Mexico. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Intranasal Breast Feeding Buserelin* / administration & dosage, adverse effects Contraceptive Agents, Female* Estrone / urine Female Humans Lactation / drug effects Menstruation / drug effects Menstruation Disturbances / chemically induced Ovulation / drug effects Postpartum Period* |
| Chemical | |
Reg. No./Substance:
|
0/Contraceptive Agents, Female; 53-16-7/Estrone; 57982-77-1/Buserelin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: GnRH agonist for postpartum contraception: biochemical, hormonal and endometrial effects.
Next Document: Beliefs about Depo-Provera among three groups of contraceptors.